RespireRx Pharmaceuticals Inc.

Equities

RSPI

US7612273059

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:29:41 04/06/2024 am IST			5-day change	1st Jan Change
0.0025 ^USD	-21.38%		+257.14%	+177.78%

10/04	RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding	CI
20/03	RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	CI

RespireRx Pharmaceuticals Inc. Appoints David Dickason as Senior Vice President Pre-Clinical Product Development

September 25, 2020 at 06:40 pm IST

RespireRx Pharmaceuticals Inc. announce the appointment on September 15, 2020, of David Dickason as Senior Vice President Pre-clinical Product Development. Mr. Dickason is a highly experienced senior executive with a proven and outstanding track record in the pharmaceutical industry.

Latest news about RespireRx Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding	10/04	CI
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	20/03	CI
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for Their Non-Opioid Lead GABAkine	13/02	CI
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dariusz Naziek to its Board of Directors	22/01	CI
Respirerx Pharmaceuticals Inc. Announces the Publication of A Case Report in Which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient	04/01	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	18/11	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	22/23/22	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23/23/23	CI
RespireRx Pharmaceuticals Inc. announced that it has received $0.25 million in funding from ARNOLD LIPPA FAMILY TRUST OF 2007	22/23/22	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	18/23/18	CI
RespireRx Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	17/23/17	CI
RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders	05/23/05	CI
RespireRx Pharmaceuticals Inc. announced that it has received $0.025 million in funding	05/23/05	CI
RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects Without Sedation	03/23/03	CI
Respirerx Pharmaceuticals Inc. Announces Appointment of Joseph Siegelbaum as Independent Member of the Board of Directors	28/23/28	CI
ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd	01/23/01	CI
RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform	12/23/12	CI
RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development	05/22/05	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	18/22/18	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	23/22/23	CI
RespireRx Pharmaceuticals Inc. Announces Board Changes	04/22/04	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	24/22/24	CI
Respirerx Pharmaceuticals Inc. Enters into First Amendment to Certain Promissory Note	16/22/16	CI
RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of Gabakine Neuromodulators for the Treatment of Tinnitus	16/22/16	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	15/22/15	CI

Chart RespireRx Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

RespireRx Pharmaceuticals Inc. develops treatments to combat disorders caused by disruption of neuronal signaling. The Company is developing treatment options that address conditions, such as obstructive sleep apnea (OSA), attention deficit hyperactivity disorder, epilepsy, acute and chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are conditions that affect millions of people, as well as certain orphan disorders such as GRIA. It also considers developing treatment options for other conditions based on results of preclinical and clinical studies to date. The Company has two business units. ResolutionRx unit holds its pharmaceutical cannabinoids platform, and is developing compounds that target the bodyâs endocannabinoid system, and in particular, the re-purposing of dronabinol for the treatment of OSA. EndeavourRx is its neuromodulators platform, which is made up of two programs: AMPAkines program and GABAkines program.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RESPIRERX PHARMACEUTICALS INC.	+177.78%	26.55L
VERTEX PHARMACEUTICALS INCORPORATED	+15.55%	12TCr
REGENERON PHARMACEUTICALS, INC.	+12.66%	11TCr
BIONTECH SE	-2.53%	2.43TCr
ARGENX SE	+1.14%	2.2TCr
GENMAB A/S	-9.35%	1.82TCr
WUXI APPTEC CO., LTD.	-42.28%	1.64TCr
BEIGENE, LTD.	-18.92%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+6.19%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+28.83%	1.23TCr

Bio Therapeutic Drugs